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ABSTRACT
This report describes our experience with reduced intensity conditioning (RIC) allogeneic hematopoietic cell
transplantation (HCT) using matched sibling and unrelated donors (MUDs) for treatment of myelofibrosis (MF).
Nine patients with MF (median age, 54 years) were treated with RIC allogeneic HCT using MUDs for 7 of the 9
patients and sibling donors for 2 patients. By the Lille classification, 4 patients were characterized as having high
risk, 4 as having intermediate risk, and 1 as having low risk. The RIC regimen consisted of fludarabine and a single
dose of total body irradiation for the first patient and fludarabine/melphalan for the remaining 8 patients. Granu-
locyte colony-stimulating factor-primed peripheral blood stem cells (PBSCs) were used for all but 1 patient who
received a total of 3 products because of graft failure, of which 2 were bone marrow cells and the third was PBSCs.
Prophylaxis against graft-versus-host disease consisted of cyclosporin/mycophenolate with or without methotrex-
ate. Seven patients were successfully engrafted with white blood cells, with an absolute neutrophil count >500 by
a median of day15 (range, 10-21 days). At the time of final fluorescence in situ hybridization and/or short tandem
repeat analysis, 8 of 9 patients were chimeric, with 96%-100% donor cells and/or DNA. Five of the 9 patients were
alive at the time of final contact, with a median follow-up of 32.2 months for the living patients. Overall survival
probability at 1 year was 55.6% (95% confidence interval, 31.3%-77.4%). These results suggest that RIC MUD
HCT using PBSCs can be an effective treatment for older patients with MF.
© 2006 American Society for Blood and Marrow Transplantation
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Idiopathic myeloﬁbrosis (MF) is a clonal hemato-
oietic disorder characterized by bone marrow ﬁbro-
is, leukoerythroblastic changes in peripheral blood,
plenomegaly, constitutional symptoms, and ex-
ramedullary hematopoiesis. The median age at diag-
osis is about 60 years, and median survival is only
bout 5 years [1,2]. Most patients die from complica-
ions of cytopenias associated with bone marrow fail-
re or leukemic transformation. Patients who present
ith polycythemia vera (P vera) or essential thrombo-
ythemia (ET) over time may present a clinical picture
ery similar to idiopathic MF, with a similarly poor irognosis. Patients with 1 or 2 of the following fea-
ures, ie, hemoglobin level 10 g/dL or a white blood
ell (WBC) count 4  109/L or 30  109/L, have
median life expectancy of 26 or 13 months, respec-
ively [3]. Other independent poor risk factors include
ge 64 years, the presence of hypercatabolic symp-
oms, circulating blasts 1%, and karyotypic abnor-
alities of 8 or 12p- [4,5].
Allogeneic hematopoietic cell transplantation (HCT)
s a potentially curative treatment approach for pa-
ients with MF that is idiopathic or secondary to
revious P vera or ET. Myeloablative conditioning
egimens have been used for most patients, with signif-
cant risks of treatment-related morbidity and mortality,
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D. S. Snyder et al.1162specially in this older patient population [6-8]. Our
nstitutional experience has been similar to that de-
cribed in these published reports. In the past few years,
educed intensity conditioning (RIC) regimens have
een developed to treat a variety of hematologic malig-
ancies. This approach relies on post-transplantation
nti-malignancy alloreactivity for the primary therapeu-
ic beneﬁt and is associated with a decrease in early
reatment-related toxicity compared with myeloablative
egimens [9-11]. Allogeneic HCT after RIC has been
pplied to older patients who have MF, with encourag-
ng results [12-16].Most of these patients were recipients
f HLA-matched sibling donor cell products, although
3 of the 21 patients reported by Kroger et al [13] had
atched unrelated donors (MUDs).
Based on these encouraging results, we have been
sing RIC for all our patients with MF who are candi-
ates for allogeneic HCT and have appropriate donors
vailable. We report our results for the ﬁrst 9 consecu-
ive patients with MF who were treated with allogeneic
CT after RIC, 7 of whom received products from
UDs. Eight of the 9 patients received peripheral blood
tem cells (PBSCs) as their primary product.
ETHODS
All patients consented to have their data analyzed
nd presented in this retrospective chart review ap-
roved by the institutional review board of the City of
able 1. Patient Demographics and Clinical Characteristics
Study
Patient
Patient Age at
HCT/Gender Lille Risk
Blast Counts
PB/BM
1 63/female Intermediate Rare/not increa
2 54/male Intermediate 2%/<2%
3 63/male Intermediate 8%/<2%
4 53/male High 3%/not increas
5 46/male High 18%/<5%
6 64/female Low 2%/not increas
7 54/female High 1%/not increas
8 58/female Intermediate 2%/not increas
9 68/male High 9%/not increas
CT indicates hematopoietic cell transplantation; PB, peripheral b
cythemia; MF, myeloﬁbrosis; HU, hydroxyurea; IFN, interferon
lineage leukemia or myeloid/lymphoid leukemia; MI, myocardi
Measured in centimeters below left costal margin.ope (Duarte, Calif). Patient and clinical character- nstics are presented in Table 1. Nine patients were
reated with allogeneic HCT for MF between May 10,
000 and February 11, 2004. The date of analysis was
ebruary 20, 2006. There were 4 women and 5 men,
ith a median age of 54 years (range, 46-68 years).
even patients were diagnosed with idiopathic MF
ased on the Italian criteria [17], whereas study patient
was originally diagnosed with P vera and patient 6
ith ET, whose conditions evolved to MF second-
rily. For all patients, the Philadelphia chromosome
nd bcr-abl gene were excluded by using standard
ethods. The interval from diagnosis of MF to HCT
anged from 8 months to 156 months (median, 41
onths). At time of transplantation, study patients 4,
, 7, and 9 were characterized as having high risk by
he Lille classiﬁcation [3], patients 1, 2, 3, and 8 as
aving intermediate risk, and patient 6 as having low
isk. All 9 patients had signiﬁcant splenomegaly as a
eature of their illness, and 5 of 9 patients underwent
plenectomy before HCT. The decision to perform
plenectomy or not was made by each physician/
atient team on a case-by-case basis. In general, it was
ecommended to proceed to splenectomy before HCT
or those patients with signiﬁcant symptoms related to
plenomegaly who were deemed suitable surgical candi-
ates. The interval from splenectomy to HCT ranged
rom 1 month to 27 months. All but study patient 1 had
1% blasts in the peripheral blood before the HCT.
atients 3, 8, and 9 had abnormal cytogenetics, although
Transfusion
of RBCs
Transfusion
of Platelets
Spleen Size at
Transplantation*
of Platelets
Yes No 2-3 cm
Yes Yes Not available; splenectomy
September 2003
Yes No 10 cm
Yes No 7.5 cm
Yes No Not available; splenectomy
February 2003
No No Not available; splenectomy
July 2001
No No Filled abdomen to right side
Yes No Not available; splenectomy
January 2001
Yes No Not available; splenectomy
September 1998
M, bone marrow; RBCs, red blood cells; ET, essential thrombo-
, cytarabine; FISH, ﬂuorescence in situ hybridization; MLL, mixed
ction; TIA, transient ischemic attack.in
sed
ed
ed
ed
ed
ed
lood; B
; Ara-C
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Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis 1163he 9 patients had constitutional symptoms. Therapies
dministered before HCT are listed in Table 1 and
ncluded hydroxyurea, anagrelide, interferon, and ima-
inib. All patients had signiﬁcant degrees of MF (2-4)
ocumented in their pre-HCT bone marrow biopsies
nd were classiﬁed as MF-3 [18]. Five patients had sig-
iﬁcant osteosclerosis.
Patients 2 and 6 had HLA matched sibling donors.
or the 7 patients who lacked suitable related donors,
LA MUDs were successfully identiﬁed through the
ational Marrow Donor Program. HLA typing was
erformed using polymerase chain reaction sequence-
peciﬁc primer or polymerase chain reaction sequence-
peciﬁc oligonucleotide probe techniques. The MUDs
ere matched at 10 of 10 loci for patients 3, 4 (ﬁrst
onor), 7, and 9; micromismatched at DQB1 for pa-
ient 1; micromismatched at HLA-B and DRB1 for
he second donor for patient 4; micromismatched at
LA-A, -B, -C, and DQB1 for patient 5; and mi-
romismatched at HLA-B and major mismatched at
LA-C for patient 8.
Study patient 9 was conditioned with a nonmyeloa-
lative regimen consisting of ﬂudarabine (Flu) 30 mg/m2
er day for 3 days on days3 to1, followed by a single
ose of total body irradiation of 200cGy on day 0. Study
atients 1-8 were conditioned with an RIC regimen
onsisting of Flu 25 mg/m2 per day for 5 days on days
6 to 2, followed by melphalan (Mel) 140 mg/m2 on
ay 1. All study patients, except for patient 4, received
resh, unmanipulated, granulocyte colony-stimulating
actor primed, PBSCs as the material for HCT. Study
atient 4 underwent 3 transplantation procedures. The
able 1. Continued
Study
Patient Cytogenetics Prior Therapy
Time
Diagn
HCT
1 Normal Procrit/imatinib
2 Normal Anagrelide 1
3 Y, 3/20, 9,der
(1:7) 16/20
Thalidomide/prednisone 123, poly
vera to
MF to
4 Normal Procrit
5 Unknown None
6 Normal HU/IFN 118, ET t
33, MF
7 Normal HU/Ara-C
8 t(4;11) 6/6, MLL
FISH negative
HU/anagrelide/imatinib
9 t(11;12), 15/15 HU/Procrit/anagrelide/IFN,
chlorambucil/Ara-C
1atient received an unprimed bone marrow product for ihe ﬁrst transplantation, granulocyte colony-stimulat-
ng factor primed PBSCs from the same donor for a
econd transplantation (performed because of primary
raft failure), and an uprimed bone marrow product
rom a second donor for a third transplantation be-
ause of primary graft failure. The conditioning reg-
mens for the 3 stem cell infusions consisted of Flu/
el for the ﬁrst and third procedures and Flu/
ntithymocyte globulin (ATG) for the second.
Prophylaxis against graft-versus-host disease (GVHD)
onsisted of cyclosporin (CSA) at 1.5 mg/kg intrave-
ously 2 times daily starting on day 1 and mycophe-
olate mofetil (MMF) at 15 mg/kg intravenously 2
imes daily starting 2 hours after stem cell infusion for
ll patients [19]. For the last 4 patients who received
UD products, “short” methotrexate (10 mg/m2 on
ay 1 and then 5 mg/m2 on days 3 and 6) was
dded to the CSA/MMF prophylaxis to improve anti-
VHD efﬁcacy. The gender combinations of donors
nd recipients and the numbers of CD34 cells/kg of
ecipient body weight contained in the stem cell prod-
cts are listed in Table 2.
ESULTS
ngraftment
Eight patients were engrafted. Study patient 4
ever was engrafted, even though this patient under-
ent 3 separate courses of conditioning followed by
nfusion of 3 stem cell products from 2 different HLA
atched MUDs (Table 3). The CD34 cell numbers
Constitutional
Symptoms
Marrow
Fibrosis Medical History
Negative 3-4/4 Unremarkable
Negative Markedly
increased
Portal vein thrombosis after
splenectomy
ia
2,
Fevers Fibrotic
spent
phase
History of polymyalgia
rheumatica
Negative Myelofibrotic Chronic hepatitis stage
2/grade 2/iron overload
Negative Myelofibrotic Unremarkable
T
Negative 4/4 Unremarkable
Night sweats,
weight loss
3/4 Family history of
polycythemia vera
(mother and brother)
Negative Myelofibrotic Cardiac arrest/MI after
splenectomy
Negative 2/4 History TIAfrom
osis to
(mo)
41
05
cythem
MF; 4
HCT
18
8
o MF;
to HC
67
21
56n all 3 stem cell products were very low (Table 2).
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D. S. Snyder et al.1164his patient was very large, with a body weight of 109
g, and he had moderate splenomegaly at the time of
ransplantation, which may have contributed to the
raft failure. His WBC count remained at 200 for
lmost his entire course. He had a transient recovery
f WBC count to a peak of 700 (absolute neutrophil
ount, 300) at day 51 after the second transplanta-
ion procedure. Fluorescence in situ hybridization
FISH) analysis of peripheral blood at that time
howed 100% host cells, and short tandem repeat
STR) analysis of bone marrow cells showed 99% host
nd 1% donor DNA. The best result achieved was
3% donor DNA by STR at day 22 after the ﬁrst
ransplantation.
Eight patients had successful WBC engraftment
ith an absolute neutrophil count 500 by day 15
range, 8-21 days). The median of WBC engraftment
or patients who had splenectomy was 13 days com-
ared with 21 days for those who still had their spleen.
he median day for platelet engraftment (25 000
ithout transfusion support in the previous 7 days)
as day32 (range, 15-594 days). In addition to study
atient 4, patient 8 expired before achieving platelet
ngraftment and patient 3 remained dependent on
latelet transfusions until his death at day 302.
All 5 surviving patients had normal karyotyping
onsistent with donor gender at the time of the most
ecent assays of bone marrow or blood.
himerism
Patients were evaluated for chimerism by using
ISH or STR DNA analysis at various time points
fter transplantations. The source of material included
nseparated bone marrow and peripheral blood for most
nalyses. For some patients, STR analyses were also
erformed on cell subsets from blood (T cells, granulo-
ytes, and monocytes) or bone marrow (T cells). Results
able 2. HCT Characteristics
Study
Patient
Conditioning
Regimen Donor Type
Stem Cell
Source Date o
1 Flu/Mel MUD PBSCs 02/11
2 Flu/Mel Sibling (brother) PBSCs 01/13
3 Flu/Mel MUD PBSCs 08/08
4 Flu/Mel MUD1 BM 06/25
Flu/ATG MUD1 PBSCs 08/12
Flu/Mel MUD2 BM 10/09
5 Flu/Mel MUD PBSCs 03/25
6 Flu/Mel Sibling (brother) PBSCs 03/11
7 Flu/Mel MUD PBSCs 07/02
8 Flu/Mel MUD PBSCs 04/19
9 Flu/TBI MUD PBSC 05/10
CT indicates hematopoietic cell transplantation; Flu, ﬂudarabine
tion; PBSCs, peripheral blood stem cells; BM, bone marrow
methotrexate; M, male; F, female.or the cell subsets were concordant with those de- tived from the unseparated material (data not shown).
ive patients achieved 100% donor chimerism and 1
atient achieved 96% donor chimerism. By FISH
nalysis, patients 1, 3, and 6 had 100% and patient 5
ad 96% donor chimerism at the time of their latest
ample. Patients 2, 7, and 8 achieved 100% donor
himerism by STR analysis. Results for study patient
, who was the only patient conditioned with a non-
yeloablative regimen, were notable because this pa-
ient demonstrated initial engraftment by day 33,
ollowed by partial loss of the graft with reemergence
f the patient’s abnormal clone by day 96 with
ssociated thrombocytopenia. After the day 153 re-
ults showed only 18% donor DNA by STR, the
atient was being considered for donor lymphocyte
nfusion and immunosuppression was withdrawn.
owever, before the patient received any additional
onditioning, his platelet count spontaneously recov-
red, and complete and sustained engraftment was
eestablished by day 237. He developed evidence of
VHD of the skin and liver when the immunosup-
ression was withdrawn, which required reinstitution
f immunosuppressive therapy to control the GVHD.
e has maintained complete engraftment ever since
hen, and the immunosuppression has been tapered.
raft-versus-Host Disease
Eight of the 9 evaluable patients developed acute
VHD. One patient had grade I, 7 had grade II-IV, and
of these 7 had grade III-IV. The 1 patient with no
cute GVHD was study patient 4 who never under-
ent engraftment. Four of the 6 patients who survived
100 days were diagnosed with extensive chronic
VHD and 1 with limited GVHD.
esolution of MF and Splenomegaly
Response of MF to HCT was assessed according
CD34 Cells in
Product/kg
GVHD
Prophylaxis
Donor/Recipient
Gender
17.1  106 CSA, MMF, MTX M/F
8.0  106 CSA, MMF M/M
2.8  106 CSA, MMF, MTX F/M
0.9  106 aspirate CSA, MMF, MTX F/M
0.7  106 concentrate F/M
2.7  106 M/M
1.1  106
2.5  106 CSA, MMF, MTX F/M
12.9  106 CSA, MMF M/F
5.2  106 CSA, MMF F/F
7.3  106 CSA, MMF M/F
2.5  106 CSA, MMF M/M
elphalan; ATG, antithymocyte globulin; TBI, total body irradia-
ells; CSA, cyclosporin A; MMF, mycophenolate mofetil; MTX,f HCT
/2004
/2004
/2003
/2003
/2003
/2003
/2003
/2003
/2002
/2002
/2000
; Mel, m
stem co the European Myeloﬁbrosis Network criteria [20].
Table 3. HCT Outcomes
Study
Patient
Overall
Survival
Splenomegaly Resolution
(days after HCT)
ANC
Engraftment*
(days after HCT)
Platelet
Engraftment†
(days after HCT)
Acute GVHD,
Grade/Organ
Chronic GVHD,
Grade/Organ
TRM at
100 d
TRM at
1 y Cause of Death
1 Alive 17 21 32 I/skin, I/liver‡, II overall Not applicable Alive Alive Not applicable
2 Alive Splenectomy before HCT 14 17 I/skin, I overall Limited, skin mild Alive Alive Not applicable
3 Expired 1 21 Transfusion
dependent
I/skin, I/GI§, II overall Extensive, skin, GI,
liver mild
Alive Expired
(302)
Respiratory failure,
alveolar
hemorrhage,
renal failure
4 Expired 36; reemerged, 83 Never engrafted Never engrafted None Not applicable Alive Expired
(125)
Graft failure, sepsis
5 Alive Splenectomy before HCT 20 55 Increased LFTs, II overall
(patient on voriconazole)
Extensive, throat, eyes,
liver mild
Alive Alive Not applicable
6 Expired Splenectomy before HCT 13 15 I/skin, IV/GI, IV/liver,
IV overall
Not applicable Expired
(52)
Expired
(52)
GVHD, sepsis
7 Alive 594 15 594 II/GI, III overall Extensive, skin, liver,
esophagus mild
Alive Alive Not applicable
8 Expired Splenectomy before HCT 10 Never engrafted III/skin, IV/GI, IV/liver,
IV overall
Not applicable Expired
(46)
Expired
(46)
GVHD, sepsis,
graft failure
9 Alive Splenectomy before HCT ANC never <500,
WBC count
never <1.5
PLT never
<50 000
II/skin, III/GI, III overall Extensive, skin, mouth,
GI, liver, eosinophilia
moderate
Alive Alive Not applicable
HCT indicates hematopoietic cell transplantation; ANC, absolute neutrophil count; GVHD, graft-versus-host disease; TRM, transplant-related mortality; GI, gastrointestinal; LFTs, liver function tests;
WBC, white blood cell; PLT, platelet count.
*ANC engraftment date occurred when the ANC was 500  103/L, achieved and sustained for 3 consecutive laboratory values on different days with no subsequent decrease.
†Platelet engraftment date occurred with a PLT of 50 000 with no transfusions in the past 7 days.
‡Liver GVH manifested as an increase in LFTs above the upper limit of normal, not by the increase in total bilirubin.
§Diarrhea volumes were never quantiﬁed, only described as “large liquid stool.” Grade I determination was based on pathologic ﬁnding of “mild” colonic GVHD.
Other contributing factors included medication effects.
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D. S. Snyder et al.1166ight of the 9 patients had follow-up bone marrow
iopsies at various time points after transplantation
1 patient expired before having a bone marrow biopsy
erformed). Of 8 patients who had core biopsies after
CT, 4 showed a decrease in grade of ﬁbrosis to
F-2 (from day 105 to 3 years after HCT). Three
atients showed no change in the degree of ﬁbrosis (at
9 days after second HCT, 71 days, and 1.5 years).
nly patient 2 showed apparent resolution of osteo-
clerosis, at 1 year, 137 days after HCT. Cellularity
as highly variable before HCT (range, 5%-70%)
nd even showed marked variability in the same pa-
ient when multiple biopsies before HCT were done
eg, 1 patient had separate biopsies before HCT rang-
ng from 5% to 50%, and another from 10% to
0%), reﬂecting that, in patients with MF, marrow
ematopoietic activity can be quite patchy and there-
ore is prone to considerable sampling variation.
Sampling bias also complicates comparisons of
ellularity before and after HCT. Cellularity after
CT was decreased in 4 of 8 patients, with 1 not
ngrafting (all 4 had 5% cellularity; at days 28 to
273). Interestingly, of these 4 patients, 3 expired
patients 3, 4, and 6). The patient who survived (pa-
ient 5) had day 71 marrow 5% without any sub-
equent biopsy. Cellularity was essentially unchanged
fter HCT in 2 patients (patients 7 and 9) and actually
ncreased in 2 (patients 1 and 2). All 5 survivors even-
ually achieved normal blood counts and transfusion
ndependence. Bone marrow karyotyping was normal
t the time of the most recent sample for all surviving
atients.
All 9 patients had splenomegaly as a feature of
F. Five of the 9 patients underwent splenectomy
efore transplantation. Splenomegaly resolved in the
ther 4 patients (transiently in study patient 4), at
igure 1. Overall survival for patients who underwent transplanta
006). Dashed lines represent 95% conﬁdence intervals.imes ranging from 30 to 594 days after transplanta-
ion.
urvival
Five of the 9 patients were alive at the time of ﬁnal
ontact, with follow-up for the living patients ranging
rom 18.6 to 67.0 months (median, 32.2 months).
or the 4 patients who expired, the causes of death
ere recurrent alveolar hemorrhage, renal failure,
epsis, and altered mental status on day  302
study patient 3); septic shock due to primary graft
ailure on day 125 after the ﬁrst transplantation
rocedure (study patient 4); sepsis due to severe
cute GVHD on day 52 (study patient 6); and
epsis with secondary graft failure due to severe
cute GVHD on day 46 (study patient 8). All 4
eaths were due to transplant-related mortality
ather than to persistent or relapsed disease. The
robability of overall survival at 1 year for these 9
atients was 55.6% (95% conﬁdence interval,
1.3%-77.4%), as is shown in a Kaplan-Meier plot
Figure 1).
uality of Life
All 5 surviving patients are independent of trans-
usions, with essentially normal blood counts. Patient
has mild thrombocytopenia with platelet counts in
he range of 115 000 without transfusion; and patient
has mild thrombocytosis with platelet counts in the
ange of 530 000. Patients 1 and 2 have no active
VHD, are off immunosuppression, and have Kar-
ovsky performance scores of 90% and 100%, respec-
ively. Patients 5, 7, and 9 have ongoing chronic
VHD that requires continuing immunosuppressive
m May 2000 to February 2004 (n  9; report date, February 20,tion fro
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Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis 1167herapy, with Karnovsky performance scores of 80%,
0%, and 80%, respectively.
ISCUSSION
This retrospective review demonstrates the feasi-
ility of treating older patients with primary or sec-
ndary MF with allogeneic HCT using PBSCs from
atched sibling or MUDs and RIC regimens. Most
atients (7 of 9) received stem cells from MUDs.
The prognosis for patients with intermediate- to
igh-risk MF is very poor, with no effective chemo-
herapy available that can change the course of the
isease [1,2,21-23]. Allogeneic HCT using fully abla-
ive conditioning regimens has been applied to this
atient population, with signiﬁcant treatment-related
ortality rates. These results have been attributed to
he toxicity of the high-dose conditioning regimens in
hese older patients, often with comorbid conditions,
roblems with engraftment related to splenomegaly
nd MF, and GVHD [6-8,24-27].
For the past several years, nonmyeloablative or
IC regimens have been used in the treatment of a
ariety of hematologic malignancies, generally for
lder patients or those with organ dysfunction. The
rinciples of this approach are to decrease early tox-
city of the conditioning regimens and to rely on the
herapeutic beneﬁt of the alloreactive immune reac-
ion, known as the graft-versus-tumor or graft-versus-
eukemia effect [9-11].
This approach was used successfully in a group of
patients with a median age of 56 years, conditioned
ith Flu/Mel, with PBSCs from matched sibling do-
ors as the source of stem cells [15]. Another report
escribed positive results for 3 patients with a median
ge of 51 years who were conditioned with Flu/busulfan
nd ATG. Two of these 3 received PBSCs from
atched siblings and the third received bone marrow
ells from a MUD [14].
More recently, Rondelli et al [12] reported results
n behalf of the Myeloproliferative Diseases-Research
onsortium for 21 patients with MF treated with
llogeneic HCT and RIC regimens. Donors for 19 of
1 patients were related and unrelated for only 2 of 21.
BSCs were the source of stem cells for 18 of 21 and
one marrow for 3 of 21. Flu/Mel was the condition-
ng regimen used for 7 of 21 patients, as was used in
ur study, and other different regimens were used in
he other 14 patients. Different prophylactic regimens
ere used to prevent GVHD. Acute GVHD of grade
II-IV developed in only 2 patients, and extensive
hronic GVHD in 8 of 18 evaluable patients. Eigh-
een patients were alive at a median follow-up of 31
onths, 17 of whom were in remission.
Another recent report from Germany describedhe investigators’ experience with 21 patients with a redian age of 53 years who were conditioned with
arious combinations of Flu/busulfan and ATG [13].
hirteen of the 21 had unrelated donors and all 21
eceived PBSCs. There were no cases of primary graft
ailure, and 20 of 21 patients had complete donor
himerism on day 100. Acute GVHD grade III-IV
ccurred in 4 of 21 patients, and 10 of 18 evaluable
atients developed chronic GVHD that was extensive
n 5 and limited in 5. The 3-year estimated overall and
isease-free survival were 84%, with a median fol-
ow-up of 22 months.
Eight of our 9 patients had successful engraftment.
nly 1 of the 9 patients had primary graft failure.
plenomegaly resolved after transplantation in the 4
atients who still had a spleen at the time of trans-
lantation. The number of patients is too small to
ake any signiﬁcant statements about the effect of
rior splenectomy on post-transplantation outcome,
lthough there was a trend towards faster WBC en-
raftment in patients who had their spleen removed
efore transplantation, similar to the report by Li et al
28]. All surviving patients demonstrated complete or
early complete chimerism by FISH or STR analysis.
The post-transplantation course of study patient 9
as informative because it demonstrates the existence
nd power of a graft-versus-malignancy effect, which
s felt to be the primary therapeutic beneﬁt of RIC
llogeneic HCT. This patient’s disease showed evi-
ence of relapse on day 96 by engraftment studies
nd by recurrence of thrombocytopenia, which was a
rominent feature of this patient’s MF. Simply by
ithdrawing the immunosuppressive drugs, the throm-
ocytopenia resolved and the patient recovered com-
lete and sustained donor engraftment by day 237.
The development of extensive chronic GVHD
as a signiﬁcant cause of morbidity and mortality in
his group of patients despite the use of prophylactic
SA/MMF and methotrexate. The older age of the
atients, the use of unrelated donors, and PBSCs as
he source of stem cells are potential contributing
actors [29]. Since the completion of this study of 9
atients, we have been using a novel prophylactic
egimen to prevent GVHD consisting of tacrolimus
nd sirolimus with or without methotrexate for older
atients with MF undergoing RIC HCT [30]. The
ollow-up for this patient population is too short to
ssess the effect of this new regimen on the incidence
f chronic GVHD and overall survival.
RIC allogeneic HCT using PBSCs for older pa-
ients with MF is a potentially curative treatment for
hose who have a well-matched sibling, as previously
eported [9-16]. The present study demonstrates that
his approach is also viable for patients who require an
nrelated donor. Engraftment is usually successful de-
pite the presence of splenomegaly and MF. GVHD
emains a signiﬁcant obstacle to long-term survival.
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